Olema Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 18, 2022 16:30 ET
|
Olema Oncology
SAN FRANCISCO, April 18, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
April 04, 2022 07:30 ET
|
Olema Oncology
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief...
Olema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 08, 2022 16:35 ET
|
Olema Oncology
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 28, 2022 16:30 ET
|
Olema Oncology
Presented Phase 1a proof-of-concept data for OP-1250 in metastatic, ER+ / HER2- breast cancer, with demonstrated attractive pharmacokinetics, favorable tolerability and encouraging anti-tumor activity...
Olema Oncology to Present at Cowen 42nd Annual Health Care Conference
February 22, 2022 07:30 ET
|
Olema Oncology
SAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2022 17:00 ET
|
Olema Oncology
SAN FRANCISCO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the...
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer
January 31, 2022 07:30 ET
|
Olema Oncology
• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part of planned leadership transition, former CMO Pamela...
Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 07:30 ET
|
Olema Oncology
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief...
Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer
November 30, 2021 07:00 ET
|
Olema Oncology
Successful completion of dose-escalation stage of ongoing Phase 1/2 clinical study; OP-1250 demonstrated highly attractive pharmacokinetics, favorable tolerability, and clear efficacy signalsRobust...
Olema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media
November 29, 2021 16:27 ET
|
Olema Oncology
SAN FRANCISCO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...